Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

Mariacarmela Santarpia,1 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Alessia Liguori,1 Elisa Giovannetti,2–4 Niki Karachaliou,5 Maria Gonzalez Cao,6 Rafael Rosell,7,8 Giuseppe Altavilla1 1Medical Oncology Unit, Department of Human Pathology &ldq...

Full description

Bibliographic Details
Main Authors: Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G
Format: Article
Language:English
Published: Dove Medical Press 2017-07-01
Series:Drug Design, Development and Therapy
Subjects:
Ceritinib
Anaplastic lymphoma kinase (ALK) gene
non-small cell lung cancer (NSCLC)
ALK tyrosine kinase inhibitors
Online Access:https://www.dovepress.com/spotlight-on-ceritinib-in-the-treatment-of-alk-nsclc-design-developmen-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/spotlight-on-ceritinib-in-the-treatment-of-alk-nsclc-design-developmen-peer-reviewed-article-DDDT

Similar Items